The Company is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other unmet medical needs.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
It's been a steep decline for Sunesis as investors balk at the long wait before the VALOR phase III trial of vosaroxin in AML in 2013. I'm not ready to buy here either, as I've seen the market caps of similar companies drop well below cash. But I'm now using CAPS as a quick reference diary of my biotech analyses, having given up on the value of scores and ratings. This green thumb will keep Sunesis on my watchlist for a potential buy at some point in 2012 if the enterprise value remains minimal.